Ernexa Therapeutics Inc.

Name: Ernexa Therapeutics Inc. standardized financial statements, quarterly
Creator: Listed

ERNANasdaqCIK 748592HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.0k, Q4 FY2024

Operating income−$4.1m, Q2 FY2026

Net income−$4.0m, Q2 FY2026

Ernexa Therapeutics Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.1	0.0	0.0	0.0	0.5	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Cost of revenue	$m	0.1	0.1	0.1	0.1	(0.1)	0.0	not reported	0.0	not reported	not reported	not reported	0.0
Gross profit	$m	(0.1)	(0.0)	(0.0)	(0.0)	0.5	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Selling, general and administrative	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$m	(5.5)	(5.8)	(5.8)	(4.9)	(2.3)	(2.7)	(2.7)	(2.5)	(2.0)	(2.1)	(5.6)	(4.1)
Interest expense	$m	not reported	not reported	0.1	0.8	1.7	(10.1)	0.8	not reported	not reported	not reported	not reported	not reported
Income tax	$m	(0.0)	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	(0.1)	(0.0)	0.0
Net income	$m	(5.6)	(6.2)	(6.6)	(5.5)	(26.6)	(5.8)	(8.2)	(3.1)	(1.2)	(1.5)	(5.5)	(4.0)
Diluted EPS	$ per share	(1.03)	not reported	(1.23)	(15.34)	(73.70)	not reported	(57.76)	(15.19)	(0.15)	not reported	(6.95)	(3.40)
Basic EPS	$ per share	(1.03)	not reported	(1.23)	(15.34)	(73.70)	not reported	(57.76)	(15.19)	(0.15)	not reported	(6.95)	(3.40)

Balance sheet

Cash and equivalents$5.0m, Q2 FY2026

Shareholders' equity$3.2m, Q2 FY2026

Ernexa Therapeutics Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	4.6	7.6	5.1	2.6	4.3	1.7	1.9	4.3	3.0	1.9	9.2	5.0
Current assets	$m	7.0	9.6	6.2	3.6	4.7	2.4	2.2	4.8	3.4	3.1	10.0	5.9
Total assets	$m	52.2	49.1	49.7	46.5	7.7	5.3	5.1	7.6	6.2	5.8	10.5	6.3
Current liabilities	$m	9.6	6.6	7.8	9.6	10.0	2.9	10.4	2.7	2.1	3.1	3.5	2.9
Total liabilities	$m	48.7	46.9	53.1	55.0	53.1	3.6	11.0	3.1	2.6	3.4	3.7	3.1
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	3.6	2.2	(3.4)	(8.5)	(45.4)	1.7	(6.0)	4.4	3.6	2.4	6.9	3.2

Cash flow

Operating cash flow−$4.2m, Q2 FY2026

Capital expenditure$3.0k, Q2 FY2026

Ernexa Therapeutics Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(5,826)	(4,661)	(3,747)	(2,259)	(6,285)	(3,545)	(2,065)	(2,532)	(1,272)	(1,148)	(2,264)	(4,152)
Capital expenditure	$k	0.0	19.0	101	249	19.0	0.0	not reported	not reported	not reported	15.0	2.0	3.0

Diluted shares (weighted)1.18m, Q2 FY2026

Ernexa Therapeutics Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	2,941	5,127	5,303	5,410	5,410	361	361	142	207	8,226	792	1,183

Shares outstanding: 1.63m at Aug 6, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. Listed shows no prices and gives no investment advice.